Novartis (NVS) Stock Price, News & Analysis

+0.75 (+0.79%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
2.45 million shs
Average Volume
1.51 million shs
Market Capitalization
$194.40 billion
P/E Ratio
Dividend Yield
Price Target

Novartis MarketRank™ Stock Analysis

Analyst Rating
2.25 Rating Score
19.9% Upside
$114.00 Price Target
Short Interest
0.21% of Float Sold Short
Dividend Strength
Based on Four Factors
News Sentiment
0.39mentions of Novartis in the last 14 days
Based on 6 Articles This Week
Insider Trading
Proj. Earnings Growth
From $7.13 to $7.94 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

Medical Sector

458th out of 910 stocks

Pharmaceutical Preparations Industry

206th out of 426 stocks

NVS stock logo

About Novartis Stock (NYSE:NVS)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

NVS Stock Price History

NVS Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Novartis begins tender offer for MorphoSys
Novartis tender offer for MorphoSys AG commences
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 3/7 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$14.85 billion
Pretax Margin


Sales & Book Value

Annual Sales
$45.44 billion
Cash Flow
$11.28 per share
Book Value
$22.87 per share


Outstanding Shares
Free Float
Market Cap
$195.77 billion

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Vasant Narasimhan M.D. (Age 48)
    Chief Executive Officer
    Comp: $8.06M
  • Mr. Harry Kirsch (Age 59)
    Chief Financial Officer
    Comp: $4.01M
  • Mr. Victor Bulto (Age 46)
    President of US
    Comp: $3.3M
  • Dr. Patrick Horber M.D. (Age 54)
    President of International
    Comp: $7.36M
  • Dr. Steffen Lang Ph.D. (Age 57)
    President of Operations
    Comp: $2.35M
  • Paul Penepent
    Head of Group Financial Reporting and Accounting
  • Dr. Samir Shah M.D. (Age 62)
    Global Head of Investor Relations
  • Dr. Klaus Moosmayer Ph.D. (Age 56)
    Chief Ethics, Risk & Compliance Officer
    Comp: $1.56M
  • Ms. Karen L. Hale (Age 56)
    Chief Legal Officer
    Comp: $2.36M
  • Dr. Robert Kowalski Pharm.D. (Age 56)
    Chief People & Organization Officer
    Comp: $2.11M

Should I Buy Novartis Stock? NVS Pros and Cons Explained


Here are some ways that investors could benefit from investing in Novartis AG:

  • Novartis AG has a strong market capitalization of $203.04 billion, indicating stability and potential for growth.
  • The company focuses on various therapeutic areas such as cardiovascular, oncology, and neuroscience, diversifying its product portfolio and reducing risk.
  • Novartis has a collaboration agreement with Alnylam Pharmaceuticals to develop inclisiran, a therapy to reduce LDL cholesterol, showing commitment to innovation and addressing healthcare needs.
  • Novartis stock has shown resilience with a 1-year high of $108.78, indicating potential for capital appreciation.
  • The company's P/E ratio of 13.34 suggests that the stock may be undervalued compared to its earnings potential, making it an attractive investment opportunity.


Investors should be bearish about investing in Novartis AG for these reasons:

  • Novartis AG's debt-to-equity ratio of 0.39 may indicate higher financial leverage, which could pose risks during economic downturns.
  • The company's current ratio of 1.15 and quick ratio of 0.93 may suggest potential liquidity challenges in meeting short-term obligations.
  • Novartis' beta of 0.54 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors seeking high returns.
  • The P/E/G ratio of 1.49 may suggest that the stock is slightly overvalued relative to its earnings growth potential, signaling caution for investors looking for undervalued stocks.
  • Novartis AG's 50-day simple moving average of $100.09 is below its 200-day simple moving average of $99.47, indicating a possible short-term bearish trend in the stock price.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

NVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price target for 2024?

4 Wall Street research analysts have issued twelve-month target prices for Novartis' stock. Their NVS share price targets range from $114.00 to $114.00. On average, they predict the company's stock price to reach $114.00 in the next year. This suggests a possible upside of 19.9% from the stock's current price.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2024?

Novartis' stock was trading at $100.97 on January 1st, 2024. Since then, NVS stock has decreased by 5.8% and is now trading at $95.11.
View the best growth stocks for 2024 here

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our NVS earnings forecast

How can I listen to Novartis' earnings call?

Novartis will be holding an earnings conference call on Tuesday, April 23rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) released its earnings results on Tuesday, January, 30th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by $0.11. The business had revenue of $11.42 billion for the quarter, compared to analysts' expectations of $11.69 billion. Novartis had a net margin of 29.83% and a trailing twelve-month return on equity of 29.90%. During the same quarter last year, the company earned $1.51 earnings per share.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Friday, March 1st. Stockholders of record on Friday, March 8th will be paid a dividend of $3.7772 per share on Thursday, March 7th. This represents a yield of 3.1%. The ex-dividend date of this dividend is Thursday, March 7th. This is an increase from the stock's previous annual dividend of $3.47.
Read our dividend analysis for NVS

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.43 per share and currently has a dividend yield of 2.58%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 33.84%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 30.60% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What ETFs hold Novartis' stock?

ETFs with the largest weight of Novartis (NYSE:NVS) stock in their portfolio include Avantis International Large Cap Value ETF (AVIV) and Avantis Responsible International Equity ETF (AVSD).Avantis International Equity ETF (AVDE).

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Who are Novartis' major shareholders?

Novartis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Scharf Investments LLC (0.06%), Raymond James & Associates (0.03%), Douglas Lane & Associates LLC (0.01%), Wealth Enhancement Advisory Services LLC (0.01%), Matthew Goff Investment Advisor LLC (0.00%) and CWM LLC (0.00%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
This page (NYSE:NVS) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners